Heart Test Laboratories - Warrants(15/06/2027) EBIT

The latest EBIT for HSCSW is $-1.9B as of January 2026. That compares with $-6.4B in the prior-year period — up 70.8% year over year. That is below the sector sector average of $-69M. Investors often review this figure alongside Heart Test Laboratories - Warrants(15/06/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, HSCSW's EBIT moved from $-6.4B to $-1.9B — a 70.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Heart Test Laboratories - Warrants(15/06/2027)'s operating scale or balance-sheet position.

Against its sector companies, HSCSW currently prints $-1.9B for EBIT, while the sector average sits near $-69M. That is roughly 2624.1% below the sector mean. Large gaps often invite a closer look at Heart Test Laboratories - Warrants(15/06/2027)'s growth, margins, and balance sheet.

A EBIT figure of $-1.9B for HSCSW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting HSCSW's EBIT ($-1.9B), review year-over-year change from $-6.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.